Company Overview

The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world’s first and only medical device that can monitor and respond to brain activity.

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company’s initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.

In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.

Corporate Officers

Frank M. Fischer

Chief Executive Officer, Board Member

Read bio

Frank Fischer has more than 30 years of senior management experience in the medical device industry. He has served on the NeuroPace Board of Directors since 1998 and joined the Company as its Chief Executive Officer in January 2000.

Prior to joining NeuroPace, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a cardiac surgery company, from May 1998 until September 1999 and served on Heartport’s Board of Directors. Mr. Fischer was President and Chief Executive Officer and a director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from 1987 until the sale of the company to St. Jude Medical, Inc. in 1997.

Before joining Ventritex, he held various management positions at Cordis Corporation in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Prior to that, he spent seven years with General Electric Company in a variety of operating positions.

Mr. Fischer holds B.S.M.E. and M.S. in Management degrees from Rensselaer Polytechnic Institute. He also serves on the Board of Directors of the Epilepsy Foundation, the Board of Trustees of Babson College and the boards of a number of privately held medical device companies.

Rebecca L. Kuhn

Chief Financial Officer, Vice President, Finance & Administration

Read bio

Rebecca Kuhn has been Chief Financial Officer and Vice President, Finance and Administration at NeuroPace since May 2000. Before joining NeuroPace, Ms. Kuhn served as Treasurer and Director of Finance at Heartport, Inc., a medical device company in the field of minimally invasive cardiac surgery.

She joined Heartport in 1992 around the company’s inception and was instrumental in completing its initial public offering in 1996. Previously, she served as an independent financial consultant to small businesses and was Director of Finance and Operations for a division of Reebok International, Inc.

She began her career in 1983 at Arthur Andersen & Co. where she worked for 4 years in the audit division. A certified public accountant (inactive status), Ms. Kuhn earned a B.S. in Business Administration from The Ohio State University, summa cum laude, and an M.B.A. from the Graduate School of Business at Stanford University.

Martha J. Morrell, MD

Chief Medical Officer

Read bio

Dr. Morrell became Chief Medical Officer of NeuroPace, Inc. in July 2004, as well as a Clinical Professor of Neurology at Stanford University. Before joining NeuroPace, she was the Caitlin Tynan Doyle Professor of Clinical Neurology at Columbia University and Director of the Columbia Comprehensive Epilepsy Center at New York Presbyterian Hospital in New York City.

Previously she was on the faculty of the Stanford University School of Medicine where she served as Director of the Stanford Comprehensive Epilepsy Center. A graduate of Stanford Medical School, she completed residency training in Neurology at University of Pennsylvania, as well as fellowship training in EEG and epilepsy. Dr. Morrell’s clinical and research work has been directed to the care of people with epilepsy.

She has more than 150 publications on epilepsy and has spoken extensively on epilepsy nationally as well as internationally. She has been a member of the Board of Directors of the American Epilepsy Society and a member and Chair of the Board of the Epilepsy Foundation.

Service to other professional societies includes the American Neurological Association as a member of the Council and the American Academy of Neurology as Chair of the Epilepsy Section. She is an elected Ambassador for Epilepsy of the International League Against Epilepsy and received the American Epilepsy Society’s 2007 Service Award for outstanding leadership and service. She is incoming President of the American Society for Experimental NeuroTherapeutics.

Isabella R. Abati

Vice President, Regulatory Affairs

Read bio

Ms. Abati has over 20 years of experience in clinical as well as regulatory affairs. Prior to joining NeuroPace in March 2005, she was Vice President of Clinical Sciences for the Neurovascular Division of Boston Scientific, Inc. (BSC).

During her six years at BSC she also had responsibility for regulatory affairs, and developed and directed both the preclinical affairs and clinical science departments. In this capacity her responsibility encompassed worldwide regulatory and clinical strategy, and the management of clinical trials.

From 1984 to 1999, Ms. Abati held progressively responsible positions in the pharmaceutical, biotech, and medical device industries in both regulatory and clinical affairs. She holds B.S. degrees in Chemistry and Medical Microbiology and an M.S. in Microbiology, all from California State University, Long Beach.

Debra L. Smolley

Vice President, Quality Assurance & Manufacturing Operations

Read bio

Deb Smolley joined NeuroPace in 2000 and was promoted to Vice President in January 2004. Ms. Smolley has over 20 years of experience in regulatory compliance and quality assurance, with more than 15 years in the medical device and pharmaceutical industries.

Before joining NeuroPace, she served as a quality systems and regulatory consultant to medical device companies. From 1993 to 1998 she held various positions at Ventritex and St. Jude Medical, Inc., most recently as Director of Regulatory Affairs. Key responsibilities included quality systems reengineering and maintenance, regulatory submissions, and ISO 9001/13485 compliance.

Ms. Smolley held previous positions in quality assurance and control at Collagen Corporation and Syntex Labs. She holds a B.S. in Microbiology from Pennsylvania State University.

NeuroPace Honors & Awards

Press Releases

November 11, 2015 in Press Release

NeuroPace RNS® System Honored With Prestigious Award — November 11, 2015

Read More
October 20, 2015 in Press Release

NeuroPace RNS® System Associated with Positive Effects In Memory and Language — October 20, 2015

Read More
February 2, 2015 in Press Release

Long-term Treatment Study Data Show Sustained Effectiveness in Adults — February 2, 2015

Read More
August 6, 2014 in Press Release

NeuroPace® RNS® System Receives Approval from CMS for New Technology Add-On Payments — August 6, 2014

Read More
November 14, 2013 in Press Release

FDA Grants Premarket Approval (PMA) for the NeuroPace RNS® System to treat Medically Refractory Epilepsy — November 14, 2013

Read More
February 25, 2013 in Press Release

FDA Advisory Panel Recommends Approval of the NeuroPace RNS® System for Medically Refractory Epilepsy — February 25, 2013

Read More
July 8, 2010 in Press Release

NeuroPace Submits PMA Application for FDA Approval of Novel Investigational Device for Epilepsy — July 8, 2010

Read More
December 7, 2009 in Press Release

Pivotal Trial Data Demonstrate NeuroPace RNS® System Reduced Seizures in People with Epilepsy — December 7, 2009

Read More